Epstein-Barr virus-associated lymphoproliferative disorders after BNT162b2 mRNA COVID-19 vaccination
-
- TANAKA Akane
- Department of Hematology and Oncology, Chiba Rosai Hospital
-
- KAWAGUCHI Takeharu
- Department of Hematology and Oncology, Chiba Rosai Hospital
-
- IMADOME Ken-Ichi
- Department of Advanced Medicine for Infections, National Center for Child Health and Development (NCCHD)
-
- HARA Satoru
- Department of Hematology and Oncology, Chiba Rosai Hospital
Bibliographic Information
- Other Title
-
- BNT162b2 mRNA COVID-19ワクチン接種後に発症したEBウイルス関連リンパ増殖性疾患
- BNT162b2 mRNA COVID-19ワクチン接種後に発症したEBウイルス関連リンパ増殖性疾患 : 第16回日本血液学会関東甲信越地方会 優秀演題
- BNT162b2 mRNA COVID-19 ワクチン セッシュ ゴ ニ ハッショウ シタ EB ウイルス カンレン リンパ ゾウショクセイ シッカン : ダイ16カイ ニホン ケツエキ ガッカイ カントウ コウシンエツチホウカイ ユウシュウ エンダイ
Search this article
Description
<p>Epstein-Barr virus-associated lymphoproliferative disorders (EBV-LPD) is a rare disease characterized by persistent or recurrent inflammation accompanied by EBV infection of T or NK cells that is not self-limiting, and it is fatal, if untreated. After receiving the first dose of the BNT162b2 mRNA COVID-19 vaccine, a 79-year-old male presented to the hospital with a 2-week history of fever. Laboratory results indicated pancytopenia, elevated liver transaminase levels, hyperferritinemia, and hypofibrinogenemia. Computed tomography revealed hepatosplenomegaly, but lymphadenopathy was not observed. A bone marrow biopsy, a random skin biopsy, and a liver biopsy revealed no malignancy, but an infectious evaluation revealed EBV viremia (5.19 Log IU/ml). Flow cytometry and RT-PCR revealed that the EBV genome was localized in NK cells, suggesting the diagnosis of EBV-NK-LPD. We administered prednisolone, intravenous immunoglobulin, and etoposide, but the EBV-DNA load failed to decrease, and he died 2 months later. Recently, case reports of COVID-19 vaccination-related hemophagocytic lymphohistiocytosis have been published. Although the mechanisms and risk factors for EBV-LPD after BNT162b2 mRNA COVID-19 vaccination remain unknown, it is important to note the possibility of reactivation of EBV after COVID-19 vaccination to initiate early and targeted therapy.</p>
Journal
-
- Rinsho Ketsueki
-
Rinsho Ketsueki 64 (4), 277-282, 2023
The Japanese Society of Hematology
- Tweet
Details 詳細情報について
-
- CRID
- 1390577386781305856
-
- NII Book ID
- AN00252940
-
- ISSN
- 18820824
- 04851439
-
- NDL BIB ID
- 032854677
-
- PubMed
- 37121772
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL
- PubMed
-
- Abstract License Flag
- Disallowed